hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06310317, orgStudyIdInfo id: CNR-IRIB-PRO-2024-003, briefTitle: Applied Behavior Analysis With Technologies, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2025-01-31, completionDateStruct date: 2025-01-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Istituto per la Ricerca e l'Innovazione Biomedica, class: OTHER, descriptionModule briefSummary: Applied Behavior Analysis (ABA) is a therapeutic approach for autism that is based on the principles of behavioral theory, learning, and positive reinforcement. Current research shows that early and intensive ABA intervention is effective in reducing dysfunctional behaviors and promoting learning and enactment of socially appropriate behaviors.In this context, new approaches that attempt to integrate advanced technologies can play a key role. This experimental protocol aims to test whether the use of advanced technologies, such as tablets, as part of an intervention for a group of children with autism spectrum disorder (ASD) is more effective than the traditional approach implemented in a control group of children with ASD. The experimental protocol is aimed at enhancing cognitive skills, increasing new skills and acquiring functional/adaptive behaviors., conditionsModule conditions: Autism, conditions: Autism Spectrum Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Applied Behavior Analysis protocol, interventions name: Traditional intervention, outcomesModule primaryOutcomes measure: Verbal Behavior Milestones Assessment and Placement Program (VB-MAPP), eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Institute for Biomedical Research and Innovation (IRIB) - National Research Council (CNR), status: RECRUITING, city: Messina, zip: 98164, country: Italy, contacts name: Flavia Marino, role: CONTACT, phone: +393395798263, email: flavia.marino@irib.cnr.it, contacts name: Maria Valeria Maiorana, role: CONTACT, phone: +393285856656, email: mariavaleria.maiorana@irib.cnr.it, contacts name: Flavia Marino, role: PRINCIPAL_INVESTIGATOR, contacts name: Giovanni Pioggia, role: SUB_INVESTIGATOR, contacts name: Paola Chilà, role: SUB_INVESTIGATOR, contacts name: Roberta Minutoli, role: SUB_INVESTIGATOR, contacts name: Noemi Vetrano, role: SUB_INVESTIGATOR, contacts name: Chiara Failla, role: SUB_INVESTIGATOR, contacts name: Germana Doria, role: SUB_INVESTIGATOR, contacts name: Ileana Scarcella, role: SUB_INVESTIGATOR, contacts name: Cinzia Grasso, role: SUB_INVESTIGATOR, contacts name: Mariaelena Franchina, role: SUB_INVESTIGATOR, geoPoint lat: 38.19394, lon: 15.55256, hasResults: False
protocolSection identificationModule nctId: NCT06310304, orgStudyIdInfo id: INCB18424-153, briefTitle: A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants., statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-03-26, primaryCompletionDateStruct date: 2024-04-16, completionDateStruct date: 2024-05-15, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Incyte Corporation, class: INDUSTRY, descriptionModule briefSummary: This study is conducted to determine the Relative Bioavailability of Ruxolitinib XR Tablets Compared With Ruxolitinib IR Tablets Administered Orally in Healthy Participants., conditionsModule conditions: Healthy Participants, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ACTUAL, armsInterventionsModule interventions name: Ruxolitinib IR, interventions name: Ruxolitinib XR, outcomesModule primaryOutcomes measure: INCB018424 pharmacokinetic (PK) in Plasma, secondaryOutcomes measure: Number of participants with Treatment Emergent Adverse Events (TEAEs), secondaryOutcomes measure: Additional INCB018424 pharmacokinetic (PK) in Plasma, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Celerion, Inc, city: Lincoln, state: Nebraska, zip: 68502, country: United States, geoPoint lat: 40.8, lon: -96.66696, hasResults: False
protocolSection identificationModule nctId: NCT06310278, orgStudyIdInfo id: 1030312, briefTitle: Ossiview Normative Mobility Data Collection Protocol, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-10-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Audioptics Medical Incorporated, class: INDUSTRY, descriptionModule briefSummary: The goal of this observational study is to learn about the sound-induced vibration level of certain structures in the middle ear in the normal-hearing population. The targeted structures are part of a chain of structures responsible for conducting sound within the auditory system and so their ability to vibrate normally in response to sound is relevant to the diagnosis of conductive hearing loss.The main questions the study aims to answer are:* What are the mean and variance of the normal sound-induced vibration level at two anatomical locations, the umbo of the malleus and the tip of the incus?* Are there any significant differences in these vibrational responses associated with sex or age?Participants will have their ossicular mobility measured with an investigational medical device that sends light into the middle ear and measures the motion-induced phase shift on light reflected from the target structures when a sound stimulus is presented. Standard hearing tests including audiometry and tympanometry will also be performed to confirm the normal hearing status of participants., conditionsModule conditions: Conductive Hearing Loss, Middle Ear, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Ossicular mobility measurement, outcomesModule primaryOutcomes measure: Umbo mobility, primaryOutcomes measure: Incus mobility, secondaryOutcomes measure: Dependence on age and sex, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06310265, orgStudyIdInfo id: TABED 1-24-21, briefTitle: Our Anesthesia Experiment Applied to Child Earthquake Victims in the February 6, 2023 Earthquake, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-12, primaryCompletionDateStruct date: 2024-04-05, completionDateStruct date: 2024-04-22, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Ankara City Hospital Bilkent, class: OTHER, descriptionModule briefSummary: The study aimed to investigate anesthesia management of pediatric patients in the Ankara Bilkent City Hospital during the earthquake disaster of February 6., conditionsModule conditions: Earthquake, conditions: Crush Injury, conditions: Anesthesia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Retrospective observational study, outcomesModule primaryOutcomes measure: The anesthesia management under pediatric earthquake victims, eligibilityModule sex: ALL, minimumAge: 30 Days, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Ankara Bilkent City Hospital, status: RECRUITING, city: Ankara, zip: 06800, country: Turkey, contacts name: Sengul Ozmert, role: CONTACT, phone: +905323861201, email: sengulozmert@yahoo.com.tr, geoPoint lat: 39.91987, lon: 32.85427, locations facility: Ankara Bilkent City Hospital,Department Of Anesthesiology and Reanimation, status: RECRUITING, city: Ankara, state: Çankaya, zip: 06800, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06310252, orgStudyIdInfo id: PRO_010-2023, briefTitle: Safety and Efficacy of an Intrastromal Transform Corneal Allograft (TCA) for Presbyopia Correction - Long Term Follow-up, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-13, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Allotex, Inc., class: INDUSTRY, descriptionModule briefSummary: The objective of this clinical study is to evaluate the long term safety and effectiveness of intrastromal implantation of the Allotex TransForm corneal allograft (TCA) for providing near vision in presbyopic subjects.A maximum of 101 eyes of qualified and consented subjects will undergo long term follow-up after instrastromal implantation of the TCA for presbyopia., conditionsModule conditions: Presbyopia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 101, type: ESTIMATED, armsInterventionsModule interventions name: Opthalmic assessments, outcomesModule primaryOutcomes measure: An exploratory data collection project with no primary safety or effectiveness endpoints., eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Gemini - Oční klinika Zlín, status: RECRUITING, city: Zlín, zip: 760 01, country: Czechia, contacts name: Stodůlka, role: CONTACT, phone: +420 577 202 202, email: info@gemini.cz, geoPoint lat: 49.22645, lon: 17.67065, locations facility: Wellington Eye Clinic, status: NOT_YET_RECRUITING, city: Dublin, zip: D18 T8P3, country: Ireland, geoPoint lat: 53.33306, lon: -6.24889, locations facility: Medipol University, status: RECRUITING, city: Istanbul, zip: 34214, country: Turkey, contacts name: Tanriverdi, role: CONTACT, phone: +904447044, email: international@medipol.com.tr, geoPoint lat: 41.01384, lon: 28.94966, locations facility: Centre For Sight, status: NOT_YET_RECRUITING, city: East Grinstead, zip: RH149 4RH, country: United Kingdom, geoPoint lat: 51.12382, lon: -0.0061, hasResults: False
protocolSection identificationModule nctId: NCT06310226, orgStudyIdInfo id: 23-000347, briefTitle: Phenotyping Response to Spinal Cord Stimulation in Chronic Low Back Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: University of California, Los Angeles, class: OTHER, descriptionModule briefSummary: Chronic low back pain (CLBP) is a debilitating condition and costly to treat. Long-term drug treatment often fails due to habituation, breakthrough of pain, or adverse effects of drug treatment. Opioid use to manage this pain has contributed to the opioid epidemic. Spinal cord stimulators have emerged as a promising treatment and reduces reliance on drugs. However, response to spinal cord stimulation (SCS) is unpredictable. It is difficult to predict which patients will respond positively to SCS because the physiological mechanism for treatment responsiveness is unclear. Therefore, the aim of this study is to investigate how spinal cord stimulators affect functional measures in patients with CLBP, including functional MRI, neurophysiology, gait analysis, and questionnaires. The results of this study can lead to the widespread adoption of spinal cord stimulators as a safe and effective therapy for CLBP, reducing the reliance on opioids and mitigating the opioid epidemic's impact., conditionsModule conditions: Chronic Low Back Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Epidural electrical spinal cord stimulator, outcomesModule primaryOutcomes measure: Detection of brain connectivity using functional MRI, secondaryOutcomes measure: Detection of brain waves using electroencephalography (EEG), otherOutcomes measure: Neurological gait kinematics assessment, otherOutcomes measure: Neurophysiological functional assessment using somatosensory evoked potential (SSEP), otherOutcomes measure: Neurophysiological functional assessment using pain-related evoked potential (PREP), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of California, Los Angeles, status: RECRUITING, city: Los Angeles, state: California, zip: 90095, country: United States, contacts name: Chau, role: CONTACT, geoPoint lat: 34.05223, lon: -118.24368, hasResults: False
protocolSection identificationModule nctId: NCT06310213, orgStudyIdInfo id: 17368, briefTitle: Non-Invasive Pressure Monitor for Neonates & Infants at Risk of Developing Hydrocephalus, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2028-06-01, completionDateStruct date: 2028-07-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Indiana University, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to test a modified smart soft contact lens in neonates and infants at risk of developing hydrocephalus. The main questions it aims to answer are:* Can the device distinguish between intracranial pressure variations in neonates and infants diagnosed with hydrocephalus and those without* Can the device compare pressure dynamics between pre- and post-operative periods in neonates and infants who undergo surgical treatments Participants will undergo standard of care evaluations for hydrocephalus (anterior fontanelle assessment and head circumference measurement) and wear the device during standard of care evaluation; pre- and post- ventricular reservoir taps, as applicable; and/or pre- and post-operatively, as applicable., conditionsModule conditions: Hydrocephalus in Infants, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: Aim 1: Comparison of neonates and infants with hydrocephalus and without Aim 2: Using smart soft contact lens (SSCL) for pre- and post-operative measurements on neonates and/or infants managed operatively (shunt placement) Aim 3: Direct validation by comparing SSCL to external ventricular drain (EVD) intracranial pressure (ICP) monitoring Aim 4: Using SSCL for pre- and post- reservoir tap measurements on neonates and/or infants managed operatively (reservoir placement) Aim 1: 10 patients per arm, two arms Aim 2: 5-10 patients, one arm Aim 3: 5-10 patients, one arm Aim 4: 5-10 patients, one arm, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Non-Invasive Pressure Monitor, outcomesModule primaryOutcomes measure: Efficacy of modified smart soft contact lens evaluation of external intracranial pressure, eligibilityModule sex: ALL, minimumAge: 0 Months, maximumAge: 12 Months, stdAges: CHILD, contactsLocationsModule locations facility: Riley Hospital for Children, city: Indianapolis, state: Indiana, zip: 46202, country: United States, contacts name: Jignesh Talior, MD, role: CONTACT, phone: 317-944-6201, geoPoint lat: 39.76838, lon: -86.15804, hasResults: False
protocolSection identificationModule nctId: NCT06310200, orgStudyIdInfo id: IRB-2023-398, briefTitle: Sphenopalatine Ganglion Block and Cold Induced Headaches, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-07-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Wright State University, class: OTHER, descriptionModule briefSummary: The primary objective of this study is to determine if a sphenopalatine ganglion (SPG) block, performed through intranasal atomization of 4% lidocaine, is able to prevent cold induced cephalgia ("Brain Freeze"). Secondary objectives will be to determine the degree of decreased pain/duration of brain freeze after sphenopalatine ganglion block, conditionsModule conditions: Cold Induced Headache, conditions: Brain Freeze, conditions: Cold Induced Cephalgia, conditions: Headache, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, maskingDescription: All besides PI, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Lidocaine Topical 4% Topical Solution, interventions name: Bitrex, interventions name: normal saline, outcomesModule primaryOutcomes measure: Does sphenopalatine ganglion (SPG) block prevent cold induced cephalgia, secondaryOutcomes measure: Degree of pain, secondaryOutcomes measure: Duration of brain freeze, secondaryOutcomes measure: Time to onset of headache, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06310174, orgStudyIdInfo id: IRB00362883, briefTitle: Study Examining the Effect of a Novel Cannulation Knife on User Satisfaction and Common Central Venous Catheter Insertion Complications, acronym: SCAD, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-22, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2027-05, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Johns Hopkins University, class: OTHER, descriptionModule briefSummary: The purpose of this study is to assess user satisfaction and the frequency of common central venous catheter insertion complications when using a novel cannulation knife., conditionsModule conditions: Central Venous Catheter Exit Site Infection, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 144, type: ESTIMATED, outcomesModule primaryOutcomes measure: User satisfaction with the new cannulation knife for CVC insertion., secondaryOutcomes measure: Frequency of skin incision revisions., secondaryOutcomes measure: Frequency of procedures being aborted and restarted., secondaryOutcomes measure: Frequency of reverting to use of the scalpel normally used to make the incision., secondaryOutcomes measure: Presence of a clean, dry dressing., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Johns Hopkins Hospital, status: RECRUITING, city: Baltimore, state: Maryland, zip: 21287, country: United States, contacts name: Lisa Fornaresio, PhD, role: CONTACT, phone: 443-927-3984, email: lisa.fornaresio@jhmi.edu, contacts name: Zyriah Robinson, role: CONTACT, phone: 443.927.3983, email: zyriah.robinson@jhmi.edu, contacts name: James Gammie, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.29038, lon: -76.61219, hasResults: False
protocolSection identificationModule nctId: NCT06310161, orgStudyIdInfo id: 855161, briefTitle: Light Therapy in End Stage Kidney Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-01, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: University of Pennsylvania, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to test light therapy in patients with end stage kidney disease who are receiving hemodialysis. The main aim is to determine if light therapy decreases fatigue severity. Participants will receive light therapy using special glasses for one hour during the dialysis sessions for four weeks of treatment., conditionsModule conditions: End Stage Renal Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Bright light, interventions name: Dim Light, outcomesModule primaryOutcomes measure: Fatigue Severity Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06310135, orgStudyIdInfo id: STUDY-23-00816, briefTitle: Filtered Eyewear to Prevent Light-induced Melatonin Suppression - Aim 1, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Icahn School of Medicine at Mount Sinai, class: OTHER, descriptionModule briefSummary: The aim of this study is to determine the relative effectiveness of monocular and binocular light exposures, with and without selective blue-blocking filtering, on nocturnal melatonin suppression, subjective sleepiness, and visual performance of night shift workers., conditionsModule conditions: Sleep Quality, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Filtered Eyewear, interventions name: Unfiltered Eyewear, interventions name: No Filters, outcomesModule primaryOutcomes measure: Melatonin Levels, secondaryOutcomes measure: Karolinska Sleepiness scale to measure Subjective Sleepiness, secondaryOutcomes measure: Numerical Verification Task (NVT), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Light and Health Research Center, city: Menands, state: New York, zip: 12204, country: United States, contacts name: Barbara Plitnick, RN, role: CONTACT, phone: 518-242-4603, email: barbara.plitnick@mountsinai.org, contacts name: Mariana Figueiro, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.69202, lon: -73.72456, hasResults: False